AC Immune S.A. (Nasdaq: ACIU)

https://www.acimmune.com

AC Immune SA is a Swiss-based biopharmaceutical company and a leader in Alzheimer´s disease drug development. AC Immune develops innovative therapeutics with "best in class" potential against Alzheimer´s disease and other conformational diseases along three axes: vaccines, antibodies and small molecules. The anti-Abeta antibody (crenezumab) for passive immunization is partnered with Genentech and is in Phase II development; it has been selected for the first groundbreaking Alzheimer's prevention trial. The company pursues the clinical development of the vaccines ACI-24 and ACI-35. These three clinical programs are focused on Alzheimer's disease, and are backed by a rich portfolio of preclinical compounds. A preclinical stage anti-Tau antibody is also partnered with Genentech. The therapeutic molecules are leveraged for Alzheimer´s disease diagnostic and other central nervous system and non-CNS diseases, such as Glaucoma and Down syndrome. Since its foundation in 2003, AC Immune has raised CHF 84 million from private investors. *

	Start	2003-02-01 established
	Industry	CNS drug
	Industry 2	crenezumab
	Person	Hornstein, Jörg (Lundbeck 202209– CFO before AC Immune + Theo Müller Group + Merck KGaA)

	Region	Lausanne VD
	Country	Switzerland
	Street	EPFL Innovation Park, Building B
	City	1015 Lausanne VD
	Tel	+41-21-6939121
		Address record changed: 2020-12-02

Basic data	Employees	D: 101 to 500 (2018-12-31)
	Currency	CHF
	Annual sales	7,194,000 (revenue, toal (2018) 2018-12-31)
	Profit	-50,951,000 (2018-12-31)
	Cash	262,500,000 (2020-06-30)

		* Document for ï¿½About Sectionï¿½:

		Record changed: 2022-04-08